newsfilter
← Latest News
Earnings Call Transcripts·

VIATRIS INC. JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - VIATRIS INC

  • Financial Performance:

    • First nine months of 2026 saw 2–3% revenue growth, 6% EBITDA growth, and 8% EPS growth compared to the same period in 2025.
    • Shifted portfolio mix toward complex generics and injectables, driving margin expansion and higher revenue predictability.
    • 50% of Chinese business is hospital-focused; 30–40% growth in e-commerce channels, now comprising 10–15% of China revenue.
    • US Estradiol patch business grew 70% year-over-year, with the company doubling its share in the transdermal segment.
    • Nashik facility fire and subsequent FDA observations resulted in an estimated $200 million revenue impact ($100M in Q3, $100M in Q4) due to plant shutdown.
    • Acquisition of Pacero Biosciences involves a purchase price multiple of 9.3x on a last-twelve-month (LTM) basis, dropping to 7.3x with synergies.
  • Guidance and Future Outlook:

    • Expects low-to-mid single-digit revenue growth in China for the full year 2026 and 2027, despite difficult comparable sales in H1 2027.
    • China growth moderation expected in H2 2026, with Q4 projected at mid-to-high single digits YoY.
    • 2027 revenue guidance assumes stability in current levels despite the Nashik facility ramp-up, as new growth drivers (US complex generics, China, Pacera) offset lower-margin OSD losses.
    • Target to restart production at Nashik in January 2027, with full capacity ramp-up expected by end of Q1 or Q2 2027.
    • Revised adjusted EBITDA midpoint guidance is $4.5 billion, driven by momentum in core businesses and new product approvals.
    • Capital allocation strategy remains balanced 50/50 between shareholder returns (dividends/buybacks) and business development over the next 4–5 years.
  • Business Segments and Product Lines:

    • US Complex Generics: Strong growth in transdermal patches (Estradiol) and respiratory devices; expanding into three generic products (Minivale, Vivaldot, Chlamyra) for the patch market.
    • China: Diverse growth across innovative, established, and generic categories; strong brand loyalty for legacy products (Lipitor, Viagra, Norvask).
    • New Product Launches: Fast-acting Meloxicam (Gynllo) PDUFA decision expected December 27; aiming for opioid-sparing language in the label.
    • Acquisition Integration: Pacera acquisition provides access to existing assets (Exondys 51, Zolreata) and commercial capabilities to accelerate Meloxicam launch.
    • Supply Chain: Added a second packaging line at the Vermont plant by late 2027; currently utilizing third-party packagers with FDA expedited approval to meet Estradiol demand.
  • Market and Competitive Landscape:

    • US HRT Market: 70% market growth driven by removal of black box warnings and increased adoption of transdermal delivery due to GLP-1 interactions affecting oral absorption.
    • Exondys 51 (from Pacera): Patent settlement allows limited entry for Furensius in 2030; company aims to extend patent protection and delay additional competition into mid-2030s.
    • China Market: Aging population and increased disposable income driving demand for quality healthcare; policy pressures concentrated in hospital channels.
    • Competitive Position: Leader in transdermal estradiol generics; leveraging strong brand equity to shift volume from hospital to retail/e-commerce in China.
  • Risks and Challenges:

    • Regulatory: FDA OAI (Official Action Indicated) classification for Nashik plant posed remediation risks; potential for warning letters or further inspections.
    • Operational: Supply constraints on high-growth Estradiol patches due to unprecedented demand; temporary reliance on third-party packagers.
    • Competition: Potential volume-limited competition for Exondys 51 starting in 2030; generic erosion risks for other portfolio items.
    • Growth Comps: Difficult year-over-year comparisons for China in H1 2027 due to strong prior-year performance.
  • Management Commentary and Tone:

    • Tone is confident and optimistic, describing 2026 as a "great year" with a "healthy" financial picture and "strong momentum" into 2027.
    • Management emphasized the successful transformation from OSD-based generics to higher-margin complex generics and international expansion.
    • Demonstrated financial discipline regarding the Pacera acquisition (low leverage impact, accretive margins) and capital allocation.
    • Acknowledged operational headwinds from Nashik but minimized impact on overall 2027 outlook, attributing revenue resilience to strong US and China performance.
  • Analyst Questions and Answers:

    • China Growth: Analysts questioned the deceleration in H2 2026; management confirmed moderate growth but maintained long-term bullishness, citing e-commerce shifts and brand loyalty.
    • Estradiol Supply: Analysts asked about sustainability and capacity; management confirmed 2x business growth, 70% market growth, and active steps to increase packaging capacity via third parties and new lines.
    • Nashik Impact: Analysts sought clarity on recovery; management confirmed $200M total impact, no revenue recovery in 2027, and a production restart target of January 2027.
    • Pacera Synergies: Analysts inquired about Exondys 51 growth rates and patent durability; management highlighted the 9.3x multiple, potential to delay competition to 2030s, and use of Pacera's hospital access for Meloxicam.
    • Meloxicam Launch: Analysts asked about PDUFA label details and pricing; management confirmed strong opioid-sparing data and a strategy focused on rapid market adoption rather than immediate high pricing, noting 5–7 year exclusivity.
  • Other Key Points:

    • Acquired Pacero Biosciences to gain in-market, high-margin US assets (Exondys 51, Zolreata) and commercial capabilities for the Meloxicam launch.
    • Gynllo (Meloxicam) is a 505(b)(2) filing with expected 5–7 years of exclusivity; Phase III data was "extraordinarily strong" regarding opioid sparing.
    • The company is an industry leader in complex generics, specifically transdermal patches, and has successfully pivoted from lower-margin OSD products.
    • China's e-commerce channel is a key strategic focus, growing 30–40% YoY and helping mitigate hospital pricing pressures.
Company
VIATRIS INC
Keywords
VIATRIS INC